Abstract
In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 65 years or above and at least 5 years previously. Fever was uncommon and did not vary by study group. The rate of local reactions increased with higher volumes of PCV and the rate following 2.0 ml of PCV was comparable to that following 0.5 ml PPV.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Aged
-
Female
-
Heptavalent Pneumococcal Conjugate Vaccine
-
Humans
-
Male
-
Meningococcal Vaccines / administration & dosage*
-
Meningococcal Vaccines / adverse effects*
-
Pneumococcal Infections / prevention & control*
-
Pneumococcal Vaccines / administration & dosage*
-
Pneumococcal Vaccines / adverse effects*
Substances
-
23-valent pneumococcal capsular polysaccharide vaccine
-
Heptavalent Pneumococcal Conjugate Vaccine
-
Meningococcal Vaccines
-
Pneumococcal Vaccines